Mr Bergh brings with him 30 years career experience as president of neuroscience products at Eli Lilly, as well as general manager of five affiliates on four continents in markets like Germany and the UK, start-up businesses in markets like Indonesia.
During his term as president of Eli Lilly’s European Operations, Mr Bergh developed its pan-European business unit to serve the interventional cardiology marketplace for the commercialisation of Eli Lilly’s market leading GP IIB/IIIA inhibitor in Europe.
Mr Bergh said: “Together we will commercialise Aggrastat (tirofiban hydrochloride) in Europe and the other regions of the world. I am convinced that Aggrastat (tirofiban hydrochloride) provides an opportunity to deliver relevant patient benefits to clinicians, payers and purchasing organisations.
“I look forward to working with all stake holders at Iroko, our management team, our customers and in particular our commercial partners, to determine the best path forward for Aggrastat (tirofiban hydrochloride).”